Develops and manufactures drugs related to immunology, neurobiology and oncology

Plexxikon, Inc. engages in the discovery and development of small molecule pharmaceuticals to treat human disease. The company's products include PLX204 for the treatment of diabetes; PLX4032 for the treatment of melanoma and colorectal cancer; and PLX5568 kinase inhibitors for the treatment of pain, polycystic kidney disease, rheumatoid arthritis, metastatic breast cancer, and renal disease. It develops a portfolio of clinical and preclinical stage programs in various therapeutic areas, including metabolic disease, such as obesity indications; oncology, such as osteolytic metastatic disease; and CNS, such as multiple sclerosis. The company’s portfolio of clinical and preclinical stage programs for other therapeutic areas include inflammation, such as systemic lupus erythematosus, inflammatory bowel disease, and osteoporosis; and cardiovascular, including hypertension and atherosclerosis.

Sanofi is a global healthcare company. Among their duties are researching disease causes, determining starting points for drug treatment, developing drugs, producing active ingredients, and delivering finished drugs and active ingredients. Specialists in vaccines, rare diseases, rare blood disorders, neurology, immunology, oncology, diabetes, cardiovascular diseases, and consumer healthcare.

Antisoma, Inc. develops drugs and pharmaceuticals. The firm's products include Xanafide, Symadex, and Clomet. Its products are used in clinical and preclinical development for multiple cancer indications. The company was founded in 2001 and is headquartered Cambridge, MA.

Eisai R&D Management Co., Ltd., a subsidiary of Eisai Co., Ltd., is a company headquartered in Bunkyo, Japan. The firm engages in research and development of pharmaceuticals.

Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic autoimmune diseases. The company’s unique technology platform allows it to locally target immune cells involved in the destruction of the diseased organ. This platform is based on the administration of Imotopes™, which are specifically modified peptides, allowing for the generation of cytolytic CD4 T-cells, that specifically eliminate antigen-presenting cells and autoantigen specific lymphocytes. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to potentially cure patients without impairing immune defense. The company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes™ for the treatment of several autoimmune diseases.

Part of Sanofi, Aventis Pharma SARL is a French company located in Antony. The firm manufactures pharmaceuticals. It was founded in 1982.

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

OncoImmune is a clinical-stage biopharmaceutical company that engages in the discovery and development of biopharmaceuticals for the treatment of cancer and autoimmune disease. It has completed a Phase II clinical trial of CD24Fc for the prophylactic treatment of acute Graft versus Host Disease for leukemia patients undergoing hematopoietic stem cell transplantation and is poised to launch a pivotal trial for the indication. Oncolmmune was founded in 2000 and is based in Rockville, Maryland.

Xention Ltd., a subsidiary of Xention Pharma Ltd., is a company headquartered in Newmarket, UK. The firm develops and researches drugs. It was founded in 2002.\nThe company says this about itself: Xention is a Cambridge-based biopharmaceutical company that was founded 2002 specialising in the discovery and development of ion channel-modulating drugs.

Croda International Plc engages in the manufacture and sale of specialty chemicals. It operates through the following business segments: Consumer Care, Life Sciences, and Industrial Specialties. The Consumer Care segment offers specialty sustainable skin care, hair care, and solar protection ingredients. The Life Sciences segment includes crop care and healthcare specialty ingredients. The Industrial Chemicals segment focuses on its biosurfactant plant at Atlas Point in North America. The company was founded by George Crowe and Henry James Dawe on May 25, 1925 and is headquartered in Goole, the United Kingdom.

The Georgia Tech Research Corp. provides research and technology support services. Its services include accounting and reports, researcher and operational support services. The comapny was founded by Preston S. Arkwright, Fuller E. Callaway, Jr. and Monie A. Ferst on April 13, 1937 and is headquartered in Atlanta, GA.

Aventis Pharma Deutschland GmbH produces pharmaceutical products. It offers prescription drugs, human vaccines, and therapeutic proteins businesses. Aventis Pharma Deutschland plans and designs plants and process control systems in the areas of active ingredients production and finished drugs. The company is headquartered in Frankfurt am Main, Germany.

Part of GSK Plc, Beecham Group Plc is a British company located in Middlesex. The firm functions as an investment holding company. It was founded in 1928.\nThe company says this about itself: The principal activity Of the Company is the holding of Intercompany bans and receipt Of interest. The Company had previously been an investment holding company. The Company is a member Of the GlaxoSmithKline Group (the 'Group\"). The directors do not envisage any change to the nature of the business in the future,

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.